# Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND

Study · id `cardio:ct-nct06954155` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06954155](<https://clinicaltrials.gov/study/NCT06954155>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06954155

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 330 participants.

## Technical summary

Registry record NCT06954155. Randomized; single masking; primary purpose treatment. Start 2025-05-30 (actual); primary completion 2027-02-28 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 330 participants (planned count; ClinicalTrials.gov record NCT06954155, source copy `cardio:ctgov-nct06954155-2026-04-01`, retrieved 2026-10-26)
- Started: 2025-05-30 (actual) (ClinicalTrials.gov record NCT06954155, source copy `cardio:ctgov-nct06954155-2026-04-01`, retrieved 2026-10-26)
- Primary completion: 2027-02-28 (anticipated) (ClinicalTrials.gov record NCT06954155, source copy `cardio:ctgov-nct06954155-2026-04-01`, retrieved 2026-10-26)
- Completion: 2027-05-30 (anticipated) (ClinicalTrials.gov record NCT06954155, source copy `cardio:ctgov-nct06954155-2026-04-01`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06954155, source copy `cardio:ctgov-nct06954155-2026-04-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06954155-2026-04-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND
- Acronym: TRACE-BEYOND
- Condition: Stroke
- Intervention (Drug): Tenecteplase (0.25mg/kg)
- Intervention (Drug): Standard medical treatment
- Lead sponsor: Beijing Tiantan Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Tenecteplase (`cardio:tenecteplase`)
- Registry intervention is a member of this class by a sourced record link: Fibrinolytic (clot-dissolving) drugs (`cardio:fibrinolytic-clot-dissolving-drugs`)
- Registry lists this organization as the lead sponsor: Beijing Tiantan Hospital (`cardio:org-beijing-tiantan-hospital`)

## Provenance

Content hash: 1ea6e5d2887cb18d89796b418165233b5138974f71f08692cd8e805ebf7949c5
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
